AAS e Colesterolo
JAMA 1989 Feb 24;261(8):1165-8
Contrasting effects of testosterone and stanozolol on serum lipoprotein levels.
Oral anabolic steroids produce striking reductions in serum concentrations of high-density lipoprotein (HDL) cholesterol. We hypothesized that this effect related to their route of administration and was unrelated to their androgenic potency. We administered oral stanozolol (6 mg/d) or supraphysiological doses of intramuscular testosterone enanthate (200 mg/wk) to 11 male weight lifters for six weeks in a crossover design. Stanozolol reduced HDL-cholesterol and the HDL2 subfraction by 33% and 71%, respectively. In contrast, testosterone decreased HDL-cholesterol concentration by only 9% and the decrease was in the HDL3 subfraction.
Apolipoprotein A-I level decreased 40% during stanozolol but only 8% during testosterone treatment. The low-density lipoprotein cholesterol concentration increased 29% with stanozolol and decreased 16% with testosterone treatment. Stanozolol, moreover, increased postheparin hepatic triglyceride lipase activity by 123%, whereas the maximum change during testosterone therapy (+25%) was not significant. Weight gain was similar with both drugs, but testosterone was more effective in suppressing gonadotropic hormones. We conclude that the undesirable lipoprotein effects of 17-alpha-alkylated steroids given orally are different from those of parenteral testosterone and that the latter may be preferable in many clinical situations.
--------------------------------------------------------------------------
COMMENTI PERSONALI:
1 - Jama e' una delle piu' quotate riviste scientifiche internazionali = articoli selezionati, maggiore garanzia di qualita' dei lavori.
2 - Dosaggi: testo enant 200 mg/week x 6 sett
win 6 mg die x 6 sett
3 - effetti sul colesterolo:
Win
HDL -33%
HDL2 -71%
ApoA -40%
LDL +29%
Azione sull'enzima epatico trigliceride lipasi +123%
Azione di soppressione delle gonadotropine MINORE
Aumento di peso = al testo (ma non dice quanto)
Testo
HDL -9% (HDL3)
HDL2 ? (non lo dice)
ApoA - 8%
LDL -16%
Azione sull'enzima epatico trigliceride lipasi +25% (non significant)
Azione di soppressione delle gonadotropine MAGGIORE
Aumento di peso = al win (ma non dice quanto)
4 - riflessioni:
> bassissima la dose di win orale, uguale aumento di peso per i due schemi. Settimanalmente sarebbero solo 42 mg (6x7) di win contro 200 di testo.
E si dice spesso che le dosi sono piu' o meno comparabili, ma sara' proprio vero?
> pesanti le alterazioni del win, almeno il testo ha abbassato anche le LDL.
Occhio al colesterolo e frazioni quando si usa il win orale ed altri 17aa orali!
Contrasting effects of testosterone and stanozolol on serum lipoprotein levels.
Oral anabolic steroids produce striking reductions in serum concentrations of high-density lipoprotein (HDL) cholesterol. We hypothesized that this effect related to their route of administration and was unrelated to their androgenic potency. We administered oral stanozolol (6 mg/d) or supraphysiological doses of intramuscular testosterone enanthate (200 mg/wk) to 11 male weight lifters for six weeks in a crossover design. Stanozolol reduced HDL-cholesterol and the HDL2 subfraction by 33% and 71%, respectively. In contrast, testosterone decreased HDL-cholesterol concentration by only 9% and the decrease was in the HDL3 subfraction.
Apolipoprotein A-I level decreased 40% during stanozolol but only 8% during testosterone treatment. The low-density lipoprotein cholesterol concentration increased 29% with stanozolol and decreased 16% with testosterone treatment. Stanozolol, moreover, increased postheparin hepatic triglyceride lipase activity by 123%, whereas the maximum change during testosterone therapy (+25%) was not significant. Weight gain was similar with both drugs, but testosterone was more effective in suppressing gonadotropic hormones. We conclude that the undesirable lipoprotein effects of 17-alpha-alkylated steroids given orally are different from those of parenteral testosterone and that the latter may be preferable in many clinical situations.
--------------------------------------------------------------------------
COMMENTI PERSONALI:
1 - Jama e' una delle piu' quotate riviste scientifiche internazionali = articoli selezionati, maggiore garanzia di qualita' dei lavori.
2 - Dosaggi: testo enant 200 mg/week x 6 sett
win 6 mg die x 6 sett
3 - effetti sul colesterolo:
Win
HDL -33%
HDL2 -71%
ApoA -40%
LDL +29%
Azione sull'enzima epatico trigliceride lipasi +123%
Azione di soppressione delle gonadotropine MINORE
Aumento di peso = al testo (ma non dice quanto)
Testo
HDL -9% (HDL3)
HDL2 ? (non lo dice)
ApoA - 8%
LDL -16%
Azione sull'enzima epatico trigliceride lipasi +25% (non significant)
Azione di soppressione delle gonadotropine MAGGIORE
Aumento di peso = al win (ma non dice quanto)
4 - riflessioni:
> bassissima la dose di win orale, uguale aumento di peso per i due schemi. Settimanalmente sarebbero solo 42 mg (6x7) di win contro 200 di testo.
E si dice spesso che le dosi sono piu' o meno comparabili, ma sara' proprio vero?
> pesanti le alterazioni del win, almeno il testo ha abbassato anche le LDL.
Occhio al colesterolo e frazioni quando si usa il win orale ed altri 17aa orali!